Residual vascular risk in diabetes - Will the SPPARM alpha concept hold the key?

Diabetes Metab Syndr. 2019 Jul-Aug;13(4):2723-2725. doi: 10.1016/j.dsx.2019.05.034. Epub 2019 May 30.
No abstract available

Publication types

  • Review

MeSH terms

  • Diabetes Mellitus, Type 2 / complications*
  • Diabetic Angiopathies / drug therapy*
  • Diabetic Angiopathies / etiology
  • Diabetic Angiopathies / metabolism
  • Humans
  • PPAR alpha / agonists*
  • PPAR alpha / antagonists & inhibitors*
  • Prognosis

Substances

  • PPAR alpha